

**REFERENCE
DOCUMENTS**



Reference Documents

Reference List

- Aoyama T, Kotaki H, Sawada Y, et al. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. *Psychopharmacology (Berl)*. 1996; 127: 117-122. Vol 1 Pg 19
- Aoyama T, Yamamoto K, Kotaki H, et al. Pharmacodynamic modeling for change of locomotor activity by methylphenidate in rats. *Pharm Res*. 1997; 14: 1601-1606. Vol 1 Pg 25
- Conners CK, March J, Frances AJ, et al. Treatment of Attention-Deficit/Hyperactivity Disorder: Expert consensus guidelines. *J Attent Disord*. 2001; 4(S1). Vol 1 Pg 31
- Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density is elevated in patients with Attention-Deficit/Hyperactivity Disorder. *Lancet*. 1999; 354:2132-2133. Vol 1 Pg 59
- Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. *In J Clin Pharmacol Ther*. 2002;40:175-184 Vol 1 Pg 61
- Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. *J Attent Disord*. 2002; 6: 89-100. Vol 1 Pg 71
- Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. *J Am Acad Child Adolesc Psychiatry*. 1996;35: 1304-1313. Vol 1 Pg 83
- Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. *J Am Acad Child Adolesc Psychiatry*. 2002;41: 26S-49S. Vol 1 Pg 93
- Krause K, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. *Neurosci Lett*. 2000;285:107-110. Vol 1 Pg 117
- Lopez F, Silva R, Pestreich L, et al. Comparative efficacy of two once daily methylphenidate formulations (RITALIN LA and CONCERTA) and placebo in children with attention deficit hyperactivity disorder across the school day. *Pediatr Drugs*. 2003; 5:545-555 Vol 1 Pg 121
- Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of Methylphenidate after oral administration of two modified-release formulations in healthy adults. *Clin Pharmacokinet*. 2003;42:393-401. Vol 1 Pg 132
- McCraken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SL1381 (ADDERALL XR), in children with ADHD. *Am Acad Child Adolesc Psychiatry*. 2003;42: 673-683 Vol 1 Pg 141
- Perel JM, Greenhill LL, Curran S, et al. Correlates of pharmacokinetics and attentional measures in methylphenidate treated hyperactive children. *Clin Pharmacol Ther*. 1991; 49:160-161. Vol 1 Pg 152

- Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. *Clin Pharmacol Ther.* 1999; 66:295-305. Vol 1 Pg 153
- Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: Proof of concept and proof of product studies. *Arch Gen Psychiatry.* 2003; 60: 204-211. Vol 1 Pg 164
- Swanson J, Gupta S, Williams L, et al. Efficacy of a new pattern of delivery of methylphenidate in the treatment of ADHD: Effects on activity level in the classroom and on the playground. *J Am Acad Child Adolesc Psychiatry.* 2002;41: 1306-1314. Vol 1 Pg 172
- Swanson J, Volkow N. Pharmacokinetic and pharmacodynamic properties of methylphenidate in humans. *Stimulant Drugs and ADHD: Basic and Clinical Neuroscience.* 2001; 259-282 Vol 1 Pg 181
- Swanson J, Wigal S, Greenhill L, et al. Analog classroom assessment of Adderall in children with ADHD. *J Am Acad Child Adolesc Psychiatry.* 1998;37: 519-526 Vol 1 Pg 206
- Swanson JM, Lerner M, Wigal T, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. *J Atten Disord.* 2002;6: S73-88 Vol 1 Pg 214 -
- Swanson JM, Volkow N. Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. *Behavioral Brain Rsch.* 2002;130:73-78. Vol 1 Pg 230
- Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS study). *Pediatrics.* 2004; 113: e206-e216 Vol 1 Pg 236
- The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder. *Arch Gen Psychiatry.* 1999;56: 1073-1086. Vol 1 Pg 247
- Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. *J Am Acad Child Adolesc Psychiatry.* 2001; 40: 188-196. Vol 1 Pg 261
- Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. *Am J Psychiatry.* 2003;160: 1909-18. Vol 1 Pg 270
- Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am J Psychiatry.* 1998;155: 1325-1331. Vol 1 Pg 280
- Volkow ND, Wang GJ, Gatley SJ, et al. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. *Psychopharmacology (Berl).* 1996;123:26-33. Vol 1 Pg 287
- Wigal S, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. *Psychopharmacol Bull.* 1998;34:47-53 Vol 1 Pg 295
- Wigal SB, Swanson JM, Greenhill L, et al. Evaluation of individual subjects in the analog classroom setting: II. Effects of dose of amphetamine (Adderall). *Psychopharmacol Bull.* 1998; 34: 833-838 Vol 1 Pg 302